Century Therapeutics Inc
NASDAQ:IPSC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sinar Mas Multiartha Tbk PT
IDX:SMMA
|
ID |
|
Guangdong JiaYuan Technology Shares Co Ltd
SSE:688388
|
CN |
|
Atari SA
PAR:ALATA
|
FR |
|
Tokyo Kiho Co Ltd
TSE:7597
|
JP |
|
Fisco Ltd
TSE:3807
|
JP |
|
Chennai Petroleum Corporation Ltd
NSE:CHENNPETRO
|
IN |
|
Sveafastigheter publ AB
STO:SVEAF
|
SE |
|
Saga Pure ASA
OSE:SAGA
|
NO |
|
G
|
Generation Capital Ltd
TASE:GNRS
|
IL |
|
Amara Raja Energy & Mobility Ltd
NSE:ARE&M
|
IN |
|
C
|
Charter Hall Long WALE REIT
OTC:CHLWF
|
AU |
|
B
|
Barloworld Ltd
JSE:BAW
|
ZA |
|
Dolfines SA
PAR:ALDOL
|
FR |
Century Therapeutics Inc
Non-Reccuring Items
Century Therapeutics Inc
Non-Reccuring Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Non-Reccuring Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Century Therapeutics Inc
NASDAQ:IPSC
|
Non-Reccuring Items
-$6.8m
|
CAGR 3-Years
12%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Non-Reccuring Items
-$5.9B
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-18%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Non-Reccuring Items
-$1.8B
|
CAGR 3-Years
24%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Non-Reccuring Items
-$7.1B
|
CAGR 3-Years
-144%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-61%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Non-Reccuring Items
-$512m
|
CAGR 3-Years
-59%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-72%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Non-Reccuring Items
-$297m
|
CAGR 3-Years
17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-32%
|
|
Century Therapeutics Inc
Glance View
Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. The company is headquartered in Philadelphia, Pennsylvania and currently employs 170 full-time employees. The company went IPO on 2021-06-17. The firm is focused on developing transformative allogeneic, pluripotent stem cells (iPSC)-derived natural killer (NK) and T cell therapies to create products for the treatment of both solid tumor and hematological malignancies. Its Allo-Evasion technology is intended to prevent rejection of cell products by the host immune system, and manufacturing capabilities intended to minimize product development and supply risk. The firm's pipeline includes CNTY-101, CNTY-103, CNTY-102 and CNTY-104. The Company’s lead product candidate, CNTY-101, is focused on targeting B-cell lymphoma. CNTY-103 is designed to treat glioblastoma. CNTY-102 is designed to improve B-cell malignancy treatment. CNTY-104, is being developed to treat acute myeloid leukemia (AML). CAR design is a component of cell therapy product candidates. In addition to its programs, the Company is also actively engaged in a number of earlier stage discovery programs.
See Also
What is Century Therapeutics Inc's Non-Reccuring Items?
Non-Reccuring Items
-6.8m
USD
Based on the financial report for Dec 31, 2025, Century Therapeutics Inc's Non-Reccuring Items amounts to -6.8m USD.
What is Century Therapeutics Inc's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 5Y
-7%
Over the last year, the Non-Reccuring Items growth was -56%. The average annual Non-Reccuring Items growth rates for Century Therapeutics Inc have been 12% over the past three years , -7% over the past five years .
